Zydus Lifesciences Ltd on Friday said it has received final approval from the US health regulator to market its generic version of Triazolam tablets used on a short-term basis to treat insomnia. The approval granted by the US Food and Drug Administration (USFDA) is to market Triazolam tablets of strengths 0.125 mg and 0.25 mg, the company said in a regulatory filing.
Zydus' Generic Triazolam Receives Approval in the U.S.
Sandoz's Generic Triazolam Receives Approval in the U.S.
Riconpharma`s Generic Triazolam Receives Approval in US
Chief Policy Officer and General Counsel Tom Moriarty recently participated in a panel at the AHIP National Health Policy Conference about drug pricing, its impact on health and financial stability, and solutions for bringing down costs and spurring innovation. Mr. Moriarty focused on the various ways CVS Health is helping to make drugs more affordable for patients and engaged in a broader discussion about policy solutions that promote the competition needed to drive down drug prices.
Drug Giant Pfizer Forced to Recall Medicines without Childproof Caps
Research and Markets: China Sleep Disorder Treatment Drugs Markets Report 2015